INTRODUCTION: According to the neurotrophin hypothesis, a brain-derived neurotrophic factor (BDNF) decrease has been postulated as a pivotal pathomechanism in affective disorder, and the treatment-associated increase in peripheral BDNF has been linked to therapeutic efficacy of antidepressant drugs and electroconvulsive therapy. However, in deep brain stimulation (DBS), a still experimental antidepressant treatment approach, this issue has not yet been investigated. METHODS: We examine the long-term course of serum BDNF levels in a 64-year-old woman who is being treated with DBS of the lateral habenula for severe major depressive disorder. RESULTS: Our main findings are a significant increase in BDNF serum levels following DBS of the lateral habenula and an inverse U-shaped correlation of depression scores and BDNF levels. DISCUSSION: The data indicate that DBS, like other effective antidepressant treatments, may contribute to an increase in peripheral BDNF levels, which are thought to reflect central nervous DBS-induced neuroplastic changes. Moreover, our observations underscore the complex nature of disease-associated BDNF alterations. Their identification as either state or trait marker remains controversial and requires larger-scale longitudinal studies.
INTRODUCTION: According to the neurotrophin hypothesis, a brain-derived neurotrophic factor (BDNF) decrease has been postulated as a pivotal pathomechanism in affective disorder, and the treatment-associated increase in peripheral BDNF has been linked to therapeutic efficacy of antidepressant drugs and electroconvulsive therapy. However, in deep brain stimulation (DBS), a still experimental antidepressant treatment approach, this issue has not yet been investigated. METHODS: We examine the long-term course of serum BDNF levels in a 64-year-old woman who is being treated with DBS of the lateral habenula for severe major depressive disorder. RESULTS: Our main findings are a significant increase in BDNF serum levels following DBS of the lateral habenula and an inverse U-shaped correlation of depression scores and BDNF levels. DISCUSSION: The data indicate that DBS, like other effective antidepressant treatments, may contribute to an increase in peripheral BDNF levels, which are thought to reflect central nervous DBS-induced neuroplastic changes. Moreover, our observations underscore the complex nature of disease-associated BDNF alterations. Their identification as either state or trait marker remains controversial and requires larger-scale longitudinal studies.
Authors: Daniel G Dillon; Isabelle M Rosso; Pia Pechtel; William D S Killgore; Scott L Rauch; Diego A Pizzagalli Journal: Depress Anxiety Date: 2013-10-21 Impact factor: 6.505
Authors: Hans-Gert Bernstein; Johann Steiner; Ulf J Müller; Moritz Ahrens; Veronika Vasilevska; Henrik Dobrowolny; Kolja Schiltz; Konstantin Schlaaff; Christian Mawrin; Thomas Frodl; Bernhard Bogerts; Tomasz Gos; Kurt Truebner Journal: Eur Arch Psychiatry Clin Neurosci Date: 2020-10-01 Impact factor: 5.270
Authors: Katrine Svenningsen; Morten T Venø; Kim Henningsen; Anne S Mallien; Line Jensen; Trine Christensen; Jørgen Kjems; Barbara Vollmayr; Ove Wiborg Journal: PLoS One Date: 2016-08-05 Impact factor: 3.240